Navigation Links
New vaccine platform may fight infections with causes from influenza to bioterrorism

uals," Dr. Kolls said. "This new technology opens up the possibility that therapeutic vaccine response can be achieved in populations of patients who face the greatest risk ?children, the immunosuppressed and the elderly.

Although not discussed in the paper, Dr. Kolls says the vaccine approach is worth investigating its potential for offering protection against weaponized agents, such as anthrax.

In mice depleted of CD4+ T cells, which are essential for signaling other cells and for producing antigen-specific antibodies, the vaccine strategy provided protection against pneumocystis. Importantly, this vaccine strategy was able to bypass the need for T cells.

A series of experiments helped identify the two key components of the experimental DNA vaccine, so called because it has only the molecular signatures of these constructs: the molecule used by activated CD4+ T cells to signal production of antibodies, and importantly, the specific fragment of pneumocystis that receptors on these antibodies recognize.

The researchers first identified as key CD40L, a molecule expressed on activated CD4+ T cells that in turn signals other cells, including B cells, to produce antibodies against the pathogen. But antibodies rely on other cells, such as dendritic cells, to capture the antigen and advertise their bounty, which they do by displaying an antigen fragment on their cell surface. Antibodies see this antigen fragment as a mug shot of sorts, and when they recognize the same fragment expressed on the on the infecting organism the antibodies give phagocytic cells the OK to consume, or eliminate, the pathogen. Through their studies, the researchers discovered a particularly potent fragment of pneumocystis, the kexin molecule, which when isolated yielded greater antibody response than pneumocystis as a whole.

In perhaps the most significant experiments the researchers conducted, mice depleted of CD4+ T cells received the combination CD40L
'"/>

Source:Children's Hospital of Pittsburgh


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
(Date:8/22/2014)... (Maximizing Access to Research Careers) Program has announced the ... & Practical Exercises Workshop which will be held on ... 25-26, 2014. These awards are meant to help ... underrepresented groups in the the FASEB Grant Writing Seminar ... 11 awards totaling $20,350. , The FASEB MARC Program ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... Molecular Biology Laboratory [EMBL] announces Luxembourg as the ... EMBL,s council and ratified by the parliament of ... as the 20th member state. "EMBL is ... Franois Biltgen, Minister of Culture, Higher Education and ...
... researchers have engineered with a novel inkjet printing method ... harmful industrial solvents and explosives. Led by MIT ... to print thin sensor films onto a microchip, a ... highly sensitive gas detectors. Mass production would ...
Cached Biology News:The key to unlocking the secret of highly specific DNAzyme catalysis 2Luxembourg joins EMBL 2MIT's 'electronic nose' could detect hazards 2MIT's 'electronic nose' could detect hazards 3
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Biotech Product with ... Direct Consumer Benefits, DES MOINES, Iowa, ... oil trait from DuPont (NYSE: DD ),will deliver increased nutritional ... market. The high oleic soybean,oil trait is the next generation of ...
... Data presented at AAAAI 64th Annual Meeting also show ... effective treatment for HAE attacks across all body sites, ... a safe and effective therapy that rapidly relieves acute,abdominal ... a rare and serious genetic disorder, according to data,presented ...
... March 18 /PRNewswire/ - Aegera Therapeutics announced ... clinical trial for AEG33773, a,novel, orally bioavailable ... painful diabetic neuropathy. The Phase I study ... of AEG33773 using a randomized,double blind, placebo ...
Cached Biology Technology:Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 2Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... for spontaneous ligand immobilization can be coupled with ... or receptor to create an affinity matrix of ... ligands via primary amines. Affi-Gel 10 gel couples ... to 11; Affi-Gel 15 gel couples acidic proteins ...
Biology Products: